Wilmer Cutler Pickering Hale and Dorr advised Ratio Therapeutics Inc in the transaction. Ratio Therapeutics Inc, a pharmaceutical company, announced its exclusive worldwide license and collaboration...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Telix Pharmaceuticals Limited in the transaction. Telix Pharmaceuticals Limited (ASX: TLX) (Telix), a biopharmaceutical company, announced its acquisition of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Navient Corporation in the offering. Navient Corporation (Nasdaq: NAVI), a provider of technology-enabled education finance and business processing solutions,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Disc Medicine, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriter. Disc Medicine, Inc. (Nasdaq: IRON) (“Disc”) announced...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Eliem Therapeutics on the deal, and Cooley advised Tenet Medicines. Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced that it had entered into...
You must be a Standard 1 Year member to access this content.
Osler, Hoskin & Harcourt acted as Canadian counsel to Milestone Pharmaceuticals Inc. in the offering, Cooleyacted as US counsel to the company. Wilmer Cutler Pickering Hale...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis represented Linden Capital Partners, Wilmer Cutler Pickering Hale and Dorr represented Alcresta Therapeutics and Wilson Sonsini Goodrich & Rosati advised HealthQuest Capital. Linden...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Kymera Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Kymera Therapeutics, Inc. (Nasdaq: KYMR) (“Kymera”) announced its...
You must be a Standard 1 Year member to access this content.
Lowenstein Sandler advised Celldex Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Celldex Therapeutics, Inc. (Nasdaq: CLDX) (“Celldex”) announced the...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Omeat Inc. in the transaction. Omeat Inc. announced it has secured $40 million in funding as it emerges from stealth...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Gemini, while Goodwin Procter advised Disc Medicine. Fried, Frank, Harris, Shriver & Jacobson acted as counsel to SVB Securities...
You must be a Standard 1 Year member to access this content.
WilmerHale advised Voyager Therapeutics on the deal. Voyager Therapeutics, a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, announced it entered into...
You must be a Standard 1 Year member to access this content.
